Potential therapeutic value of lazaroids in endotoxemia and other forms of sepsis

Shock

Volumn 8, Issue 5, 1997, Pages 321-327

  Spapen, Herbert ^a   Zhang, Haibo ^a   Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

21 [4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]PREGNA 1,4,9(11) TRIENE 3,20 DIONE; ANTIOXIDANT; DRUG DERIVATIVE; GLUCOCORTICOID; METHYLPREDNISOLONE; PREGNANE DERIVATIVE; SCAVENGER; TIRILAZAD;

ANIMAL; CHEMISTRY; DRUG EFFECT; ENDOTHELIUM; ENDOTOXEMIA; HUMAN; REPERFUSION INJURY; REVIEW; SEPSIS; SEPTIC SHOCK; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIOXIDANTS; ENDOTHELIUM; ENDOTOXEMIA; FREE RADICAL SCAVENGERS; GLUCOCORTICOIDS; HUMANS; METHYLPREDNISOLONE; PREGNATRIENES; REPERFUSION INJURY; SEPSIS; SHOCK, SEPTIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031264110     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199711000-00002     Document Type: Article

References (79)

1. Bone RC: The pathogenesis of sepsis. Ann Intern Med 115:457-469, 1991.
2. McCuskey RS, Urbaschek R, Urbaschek B: The microcirculation during endotoxemia. Cardiovasc Res 32:752-763, 1996.
3. Carlet J, Cronin L: Critical reappraisal of steroids and other anti-inflammatory agents. In: Clinical trials for the treatment of sepsis. Sibbald WJ, Vincent J-L (eds), Heidelberg: Springer-Verlag, 1995, pp. 251-266.
4. Knowles RG, Salter M, Brooks SL, Moncada S: Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun 172:1042-1048, 1990.
5. Schumer W: Steroids in the treatment of clinical septic shock. Ann Surg 184:333-341, 1976.
6. Sprung CL, Caralis PV, Marcial EH, et al: The effects of high-dose corticosteroids in patients with septic shock: A prospective, controlled study. N Engl J Med 311:1137-1143, 1984.
7. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA, The Methylprednisolone Severe Sepsis Study Group: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653-658, 1987.
8. The Veterans Administration Systemic Sepsis Cooperative Study Group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659-665, 1987.
9. Hall ED: Effects of the 21-aminosteroid U74006F on posttraumatic spinal cord ischemia in cats. J Neurosurg 68:462-465, 1988.
10. Bracken MB, Shepard MJ, Collins WF, et al: A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinalcord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322:1405-1411, 1990.
11. McCord JM: Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312:159-163, 1985.
12. Slater TF: Free radical mechanisms in tissue injury. Biochem J 222:1-15, 1984.
13. Albano E, Bellomo G, Parola M, Carini R, Dianzani MU: Stimulation of lipid peroxidation increases the intracellular calcium content of isolated hepatocytes. Biochem Biophys Acta 1091:310-316, 1991.
14. Siesjö BK: Calcium and cell death. Magnesium 8:223-237, 1989.
15. Sibbald WJ, Driedger AA, Finley R, et al: High-dose corticosteroids in the treatment of pulmonary microvascular injury. Ann NY Acad Sci 384:496-516, 1982.
16. Goldstein JM, Roos D, Weisman G, Kaplan HB: Influence of corticosteroids on human polymorphonuclear leukocyte function in vitro: Reduction of lysosomal enzyme release and superoxide production. Inflammation 1:305-315, 1976.
17. Braughler JM: Lipid peroxidation-induced inhibition of gamma-aminobutyric acid uptake in rat brain synaptosomes: Protection by glucocorticoids. J Neurochem 44:1282-1288, 1985.
18. +)- ATPase activity. Dose-response analysis during first hour after contusion injury in the cat. J Neurosurg 57:247-253, 1982.
19. Braughler JM, Pregenzer JF, Chase RL, Duncan LA, Jacobsen EJ, McCall JM: Novel 21-aminosteroids as potent inhibitors of iron-dependent lipid peroxidation. J Biol Chem 262:10438-10440, 1987.
20. Althaus JS, Williams CM, Andrus PK, et al: In vitro and in vivo analysis of tirilazad (U-74006F) as a hydroxyl radical (·OH) scavenger. Neurosci Abstr 17:164, 1991 (abstract).
21. Braughler JM, Pregenzer JF: The 21-aminosteroid inhibitors of lipid peroxidation: Reactions with lipid peroxyl and phenoxy radicals. Free Rad Biol Med 7:125-130, 1989.
22. Sato PH, Hall ED: Tirilazad mesylate protects vitamins C and E in brain ischemia-reperfusion injury. J Neurochem 58:2263-2268, 1992.
23. Fleckenstein AE, Smith SL, Linseman KL, Beuving LJ, Hall ED: Comparison of the efficacy of mechanistically different antioxidants in the rat hemorrhagic shock model. Circ Shock 35:223-230, 1991.
24. Thomas PD, Mao GD, Rabinovitch A, Poznansky MJ: Inhibition of superoxide-generating NADPH oxidase of human neutrophils by lazaroids (21-aminosteroids and 2-methylaminochromans). Biochem Pharmacol 45: 241-251, 1993.
25. Hinzmann JS, McKenna RL, Pierson TS, Han F, Kedzy FJ, Epps DE: Interaction of antioxidants with depth-dependent fluorescence quenchers and energy transfer probes in lipid bilayers. Chem Phys Lipids 62:123-138, 1992.
26. Audus KL, Guillot FL, Braughler JM: Evidence for 21-aminosteroid association with the hydrophobic domains of brain microvessel endothelial cells. Free Rad Biol Med 11:361-371, 1991.
27. Braughler JM, Chase RL, Neff GL, et al: A new 21-aminosteroid antioxidant lacking glucocorticoid activity stimulates adrenocorticotropin secretion and blocks arachidonic acid release from mouse pituitary tumor (AtT-20) cells. J Pharmacol Exp Ther 244:423-427, 1988.
28. Munns PL, Leach KL: Two novel antioxidants, U74006F and U78517F, inhibit oxidant-stimulated calcium influx. Free Rad Biol Med 18:467-478, 1995.
29. + pump ATPase of human red blood cell membranes. Biochem Pharmacol 46:525-534, 1993.
30. Zhang H, Spapen H, Manikis P, et al: Tirilazad mesylate (U-74006F) inhibits effects of endotoxin in dogs. Am J Physiol 268:H1847-H1855, 1995.
31. Semrad SD, Rose ML, Adams JL: Effect of tirilazad mesylate (U74006F) on eicosanoid and tumor necrosis factor generation in healthy and endotoxemic neonatal calves. Circ Shock 40:235-242, 1993.
32. Shenkar R, Abraham E: Effects of treatment with the 21-aminosteroid, U74389F, on pulmonary cytokine expression following hemorrhage and resuscitation. Crit Care Med 23:132-139, 1995.
33. Meyer RJ, Juarez RA, Holden WE: 21-aminosteroids protect endothelial cells against injury by neutrophils. Am Rev Respir Dis 145:A571, 1992.
34. Kitt TM, Luderer JR, Shappell SB, Mitchell JR, Taylor AA, Smith CW: The effect of U74006F, a novel 21-aminosteroid on human neutrophil function. FASEB J 3:A595, 1989 (abstract).
35. Gadaleta D, Verma M, Davis JM: Inhibition of neutrophil leukotriene generation by the 21-aminosteroid, U-74389F. J Surg Res 57:233-237, 1994.
36. McKenna R, Munns PL, Leach KL, Mathews WR: Vascular effects of the 21-aminosteroid tirilazad mesylate: Protection against oxidant stress. Methods Find Exp Clin Pharmacol 17:279-292, 1995.
37. Kanamaru K, Weir BKA, Findlay JM, Grace M, MacDonald RL: A dosage study of the effect of the 21-aminosteroid U-74006F on chronic cerebral vasospasm in a primate model. Neurosurgery 27:29-38, 1990.
38. Matsui T, Asano T: Effects of new 21-aminosteroid tirilazad mesylate (U-74006F) on chronic cerebral vasospasm in a "two hemorrhage" model of beagle dogs. Neurosurgery 34:1035-1039, 1994
39. Cosenza CA, Cramer DV, Cunneen SA, Tuso PJ, Wang HK, Makowka L: Protective effect of the Iazaroid U74006F in cold ischemia-reperfusion injury of the liver. Hepatology 19:418-425, 1994.
40. Eversole RR, Smith SL, Beuving LG, Hall ED: Protective effect of the 21-aminosteroid lipid peroxidation inhibitor tirilazad mesylate (U74006F) on hepatic endothelium in experimental hemorrhagic shock. Circ Shock 40:125-131, 1993.
41. Squadrito F, Altavilla D, Ammendolia L, et al: Improved survival and reversal of endothelial dysfunction by the 21-aminosteroid, U-74389G in splanchnic ischaemia-reperfusion injury in the rat. Br J Pharmacol 115: 395-400, 1995.
42. Dimmeler S, Brinkmann S, Neugebauer E: Endotoxin-induced changes of endothelial cell viability and permeability: Protective effects of a 21-aminosteroid. Eur J Pharmacol 287:257-261, 1995.
43. Siegfried MR, Ma X, Lefer AM: Splanchnic vascular endothelial dysfunction in rat endotoxemia: Role of superoxide radicals. Eur J Phannacol 212:171-176, 1992.
44. Schmidt H, Schmidt W, Muller T, et al: Effect of the 21-aminosteroid tirilazad mesylate on leukocyte adhesion and macromolecular leakage during endotoxemia. Surgery 121:328-334, 1997.
45. Liu P, Vonderfecht SL, Fisher MA, McGuire GM, Jaeschke H: Priming of phagocytes for reactive oxygen production during hepatic ischemia-reperfusion potentiates the susceptibility for endotoxin-induced liver injury. Circ Shock 43:9-17, 1994.
46. Lesiuk H, Sutherland G, Peeling J, Butler K, Saunders J: Effect of U74006F on forebrain ischemia in rats. Stroke 22:896-901, 1991.
47. Wilson JT, Bednar MM, McAuliffe TL, Raymond S, Gross CE: The effect of the 21-aminosteroid U74006F in a rabbit model of thromboembolic stroke. Neurosurgery 31:929-934, 1992.
48. Perkins WJ, Newberg Milde L, Milde JH, Michenfelder JD: Pretreatment with U74006F improves neurologic outcome following complete cerebral ischemia in dogs. Stroke 22:902-909, 1991.
49. Natale JE, Schott RJ, Hall ED, Braughler JM, D'Alecy LG: Effect of the aminosteroid U74006F after cardiopulmonary arrest in dogs. Stroke 19: 1371-1378, 1988.
50. Carrea FP, Lesnefsky EJ, Kaiser DG, Horwitz LD: The lazaroid U74006F, a 21-aminosteroid inhibitor of lipid peroxidation, attenuates myocardial injury from ischemia and reperfusion. J Cardiovasc Pharmacol 20:230-235, 1992.
51. Levitt MA, Sievers RE, Wolfe CL: Reduction of infarct size during myocardial ischemia and reperfusion by lazaroid U-74500A, a nonglucocorticoid 21-aminosteroid. J Cardiovasc Pharmacol 23:136-140, 1994.
52. Holzgrefe HH, Buchanan LV, Gibson JK: Effects of U74006F, a novel inhibitor of lipid peroxidation, in stunned reperfused canine myocardium. J Cardiovasc Pharmacol 15:239-248, 1990.
53. Ovize M, de Lorgeril M, Ovize A, Ciavatti M, Delaye J, Renaud S: U74006F, a novel 21-aminosteroid, inhibits in vivo lipid peroxidation but fails to limit infarct size in a canine model of myocardial ischemia reperfusion. Am Heart J 122:681-689, 1991.
54. Salem YH, Dulchavsky SA, Dutta S, Diebel LN: Effect of inhibition of lipid peroxidation on myocardial oxidant damage. J Surg Res 56:606-610, 1994.
55. Johnson G III, Lefer AM: Protective effects of a novel 21-aminosteroid during splanchnic artery occlusion shock. Circ Shock 30:155-164, 1990.
56. Todo S, Hamada N, Zhu Y, et al: Lazaroid U-74389G for 48-hour canine liver preservation. Transplantation 61:189-194, 1996.
57. Stanley JJ, Goldblum JR, Frank TS, Zelenock GB, D'Alcey LG: Attenuation of renal reperfusion injury in rats by the 21-aminosteroid U74006F. J Vasc Surg 17:685-689, 1993.
58. Shackleton CR, Ettinger SL, Scudamore CH, Toleikis PF, Keown PA: Effect of a 21-aminosteroid, U74006F, on lipid peroxidation and glomerulotubular function following experimental renal ischemia. J Surg Res 57:433-437, 1994.
59. Hall ED, Yonkers PA, McCall JM: Attenuation of hemorrhagic shock by the non-glucocorticoid 21-aminosteroid U74006F. Eur J Pharmacol 147: 299-303, 1988.
60. Aoki N, Lefer AM: Protective effects of a novel nonglucocorticoid 21-aminosteroid (U74006F) during traumatic shock in rats. J Cardiovasc Pharmacol 15:205-210, 1990.
61. Curzen NP, Griffiths MJD, Evans TW: Role of the endothelium in modulating the vascular response to sepsis. Clin Sci 86:359-374, 1994.
62. Goode HF, Webster NR: Free radicals and antioxidants in sepsis. Crit Care Med 21:1770-1776, 1993.
63. Galley HF, Davies MJ, Webster NR: Xanthine oxidase activity and free radical generation in patients with septic syndrome. Crit Care Med 24: 1649-1653, 1996.
64. Liu P, McGuire GM, Fisher MA, Farhood A, Smith CW, Jaeschke H: Activation of Kupffer cells and neutrophils for reactive oxygen formation is responsible for endotoxin-enhanced liver injury after hepatic ischemia. Shock 3:56-62, 1995.
65. Liu P, Vonderfecht SL, McGuire GM, Fisher MA, Farhood A, Jaeschke H: The 21-aminosteroid tirilazad mesylate protects against endotoxin shock and acute liver failure in rats. J Pharmacol Exp Ther 271:438-445, 1994.
66. McGuire GM, Liu P, Jaeschke H: Neutrophil-induced lung damage after hepatic ischemia and endotoxemia. Free Rad Biol Med 20:189-197, 1996.
67. Fisher MA, Eversole RR, Beuving LJ, Jaeschke H: Sinusoidal endothelial cell and parenchyma! cell injury during endotoxemia and hepatic ischemia-reperfusion: Protection by the 21-aminosteroid tirilazad mesylate. Int Hepat Comm 1997. In press.
68. Wang Y, Mathews WR, Guido DM, Jaeschke H : The 21-aminosteroid tirilazad mesylate protects against liver injury via membrane stabilization not inhibition of lipid peroxidation. J Pharmacol Exp Ther 277:714-720, 1996.
69. McKenna R, Laskey RE, Wang Y, Jaeschke H, Mathews WR: Effect of endotoxin-enhanced hepatic reperfusion injury on endothelium-dependent relaxation in rat aorta. Shock 6:106-111, 1996.
70. Rose ML, Semrad SD: Clinical efficacy of tirilazad mesylate for treatment of endotoxemia in neonatal calves. Am J Vet Res 53:2305-2310, 1992.
71. Powell RJ, Machiedo GW, Rush Jr BF, Dikdan OS: Effect of oxygen-free radical scavengers on survival in sepsis. Am Surg 57:86-88, 1991.
72. Lorenzl S, Koedel U, Frei K, Bernatowicz A, Fontana A, Pfister H-W: Protective effect of a 21-aminosteroid during experimental pneumococcal meningitis. J Infect Dis 172:113-118, 1995.
73. Semrad SD: Comparison of flunixin, prednisolone, dimethyl sulfoxide, and a Iazaroid (U74389F) for treating endotoxemic neonatal calves. Am J Vet Res 54:1517-1522, 1993.
74. Lehmann CH, Egerer K, Georgiew A, Weber M, Kox WJ: Inhibition of tumour necrosis factor-a release in rat experimental endotoxaemia by treatment with the 21-aminosteroid U-74389G. Intensive Care Med 22(SuppI 3):S338, 1996 (abstract).
75. Krysztopik RJ, Bentley FR, Spain DA, Wilson MA, Garrison RN: Free radical scavenging by Iazaroids improves renal blood flow during sepsis. Surgery 120:657-662, 1996.
76. Johnson D, Hurst T, Prasad K, et al: Lazaroid pretreatment preserves gas exchange in endotoxin-treated dogs. J Crit Care 9:213-223, 1994.
77. Tanigaki T, Suzuki Y, Heimer D, Sussman HH, Ross WG, Raffm TA: Attenuation of acute lung injury and oxygen radical production by the 21-aminosteroid, U-78518F. J Appl Physiol 74:2155-2160, 1993.
78. Remmers D, Dwenger A, Grotz M, et al: Attenuation of multiple organ dysfunction in a chronic sheep model by the 21-aminosteroid U74389G. J Surg Res 62:278-283, 1996.
79. Kassell NF, Haley EC Jr, Apperson-Hansen C, Alves WM: Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in Europe, Australia, and New Zealand. J Neurosurg 84:221-228, 1996.